Cellectar teams up with Orano Med to develop new cancer therapy [Seeking Alpha]
Cellectar Biosciences, Inc. (CLRB)
Last cellectar biosciences, inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cellectar.com
Company Research
Source: Seeking Alpha
Cellectar Biosciences ( CLRB ) will collaborate with Orano Med (formerly AREVA Med) to develop a new phospholipid-drug conjugate (PDC) for the treatment of cancer. The PDC will consist of Orano's radioisotope lead-212 conjugated to Cellectar's phospholipid ether. Lead-212 is an alpha emitter which delivers higher energy over a shorter distance than other radioisotopes. The higher energy from alpha particles causes non-repairable DNA damage which kills cancer cells and may provide greater efficacy at lower doses with less side effects. The companies intend to evaluate the candidate in up to three cancer types. Under the terms of the partnership, early preclinical costs will be equally shared. Either party will have the option to advance and commercialize the PDC alone or in collaboration with the other. The option is exercisable after early proof-of-concept data. Click to subscribe to real-time analytics on CLRB Now read: Does Tesaro Really Deserve The Beatdo
Show less
Read more
Impact Snapshot
Event Time:
CLRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLRB alerts
High impacting Cellectar Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CLRB
News
- Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven? [Yahoo! Finance]Yahoo! Finance
- Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.MarketBeat
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
CLRB
Sec Filings
- 4/25/24 - Form SC
- 4/1/24 - Form 10-K/A
- 3/27/24 - Form 8-K
- CLRB's page on the SEC website